Mark Cuban In the News – Backs Startup ‘ChatableApps’ Launches World’s First Universal Hearing Aid

May 27, 2020

ChatableApps has today launched the world’s first universal hearing aid, using neuroscience-led artificial intelligence to enable those suffering from hearing loss to hear one-to-one conversations clearly, using an everyday smartphone and a standard pair of earbuds.

Hearing loss affects 37.5mn adults in the U.S.* and the World Health Organisation has stated that 466mn** people globally have ‘disabling hearing loss’, with this expected to reach 900mn by 2050. However, due to the high cost of traditional hearing aids and lack of inclusion in medical insurance many of those suffering are currently going untreated.

Serial entrepreneur Mark Cuban, who provided early investment in the technology, said: “Chatable is using AI to address growing health care inequality by providing an affordable hearing aid app that helps with conversation.”

Founder and chief scientist at ChatableApps, Dr Andrew Simpson (PhD) – a pioneer of neuroscience-led AI – has devised a brand new way of thinking about AI which reverse engineers the neural processes of the hearing brain and implements them as AI. This gives you an AI on your phone that works like a brain to make conversation easy to hear. Essentially, sound goes in complicated and comes out simple.

“Putting an auditory cortex on a smartphone has been a dream for a long time. As far as I know this is the most advanced real-time AI that has ever gone on a phone” said Dr Simpson. “It’s been a long road, but our preclinical trials reveal something of a medical breakthrough: a hearing aid that doesn’t need hearing tests and going straight into the hands of people who can’t afford a hearing aid.”

The performance levels Dr Simpson’s approach achieves surpass those of a traditional hearing aid when it comes to one-to-one conversation. This was confirmed in pre-clinical trials where 86% reported that the ChatableApps universal hearing aid was better for conversation than their traditional hearing aid.

Despite the complex science and AI at work in the app, the user interface is simple. Once downloaded, the user simply moves two sliders up and down to find their desired balance. The volume boost slider enables clear and loud voice, while the background noise slider removes background noise, allowing users to hear conversations no matter where they are.

“Our unique ground-up AI makes our universal hearing aid the first app capable of addressing the global hearing epidemic.” Giles Tongue, ChatableApps CEO, commented. “Following successful preclinical trials we have decided to launch immediately due to urgent demand from audiologists to help people struggling because of Coronavirus. With many unable to lipread due to face masks or unable to visit a hearing clinic in an emergency, our app provides a lifeline that will help people communicate.”

The ChatableApps Universal Hearing Aid app is available to download now on iOS and Android. The app is free to access, with the option to subscribe to unlock maximum voice amplification and reduction of background noise. The full version is available for $12.99 /monthly, $79.99 /annual.

iOS: https://apps.apple.com/gb/app/chatable-hearing-aid/id1494968908
Android: https://play.google.com/store/apps/details?id=com.hearingaid.volumebooster&hl=en_GB


References

*figures taken from – https://www.nidcd.nih.gov/health/statistics/quick-statistics-hearing
**taken from the World Health Organisation’s ‘Global estimates on prevalence of hearing loss’ (2018)

In pre-clinical trials:

● 76% said conversation was easier because of our background noise slider, 15% in a life changing way

● 80% said conversation was easier because of our volume boost (and that was before we beefed it up), 15% in a life changing way.

● 86% reported app was better for conversation than their hearing aid.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”